ICH Project 52nd ICH Public Meeting (Online)

December 16, 2025

To widely share information on ICH developments with representatives from companies responsible for pharmaceutical development, safety, and quality assurance, as well as the general public, the 52nd ICH Immediate Report Meeting will serve as a forum for presenting and reporting the outcomes of the ICH Singapore Meeting(November 15–19, 2025), we will host the 52nd ICH Public Meeting online on December 17, 2025.

At this briefing, we will first report on ICH trends, including the results of the Singapore meeting. We will then feature presentations and Q&A sessions with experts from various working groups on quality, safety, efficacy, and cross-cutting issues.
The program and schedule for this briefing are attached below as a file, which you can view directly.
Please note that unauthorized copying or reproduction of the attached content is prohibited.

Date, Time, and Venue

Date and Time Format
Wednesday, December 17, 2025, 1:00 PM – 5:05 PM Online (Zoom)

Information and Program

Event Information / Program

You can scroll horizontally

Presentations Speakers
01-1_ICH Trends Fumiya Tamura (MHLW)
01-2_ICH Trends - From the Perspective of the JPMA- Masafumi Yokota (JPMA)
02_Q1 EWG: Stability Testing of Drug Substances and Drug Products Junji Ohashi (JPMA)
03_Q6(R1): Revision of the Specifications Guidelines Atsuko Rōyū (PMDA)
04_Q9(R1) Training Group: Revision of "Quality Risk Management" Tomonori Nakagawa (JPMA)
05_S13 EWG: Nonclinical Safety Studies for Oligonucleotide-based Therapeutics Takasumi Shimomoto (NIH)
06_E14/S7B IWG: E14/S7B Questions and Answers-
Clinical and Nonclinical Evaluation of QT/QTc
Interval Prolongation and Proarrhythmic Potential
Satoshi Tsunoda (PMDA)
07_E21 EWG: Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials Yoko Motoki (General Organization)
08_E23 EWG: Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision Making with a Focus on Effectiveness of Medicines Ryota Kimura (PMDA)
09_M7 Sub-group: Addendum to "Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk" Kiyohiro Hashimoto (JPMA)
10_M11 EWG: Clinical electronic Structured Harmonised Protocol Hiroshi Sakaguchi (PMDA)
11_M13 EWG: Bioequivalence for Immediate-Release Solid Oral Dosage Forms Hideaki Kuribayashi (NIH)
12_M15 EWG: General Principles Regarding Model-Informed Drug Development Kinya Nakai (JPMA)
13_M18 EWG: Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs Naohiro Otaki (PMDA)
 

Share this page

TOP